NxStage and Spindial Announce Partnership with Niguarda-Ca' Granda Hospital in Milan
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
Logo - http://photos.prnewswire.com/prnh/20150624/225341
Patients can have the amazing opportunity to more easily discover the famous architecture of Milan or visit the Universal EXPO, being held until October 31, 2015. NxStage, Spindial, and Niguarda-Ca' Granda look forward to welcoming patients in Italy.
For further information on on this program, please contact local customer care service:
-In Italy: [email protected] , +39 (0) 346 373 3232
-In North America: [email protected] , +1-866-NXSTAGE (+1-866-697-8243)
-In United Kingdom: [email protected] , +44 (0) 800 048 8352
-In other countries: contact a local distributor: http://www.nxstage.com/ourcompany/global-partners.
The NxStage System One is a prescription device. All forms of hemodialysis, including treatments performed in-center, in-hospital and at home, involve some risks. In addition, there are certain risks unique to treatment in the home environment. Patients should talk to their doctor and dialysis clinic to understand if they are healthy enough to travel internationally and whether this program is medically appropriate for them.
The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Travel requirements are unique depending upon the jurisdiction a patient may travel from and to. Patients should speak with their physician and treating dialysis clinic to understand what requirements they may need to satisfy in order to travel to Milan, Italy and receive treatment there. Patients should also speak with appropriate regulatory authorities to further understand these requirements.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
[email protected]
Tel: +1-978-332-5923
